LY4050784 + pembrolizumab + carboplatin + nab-paclitaxel

LY4050784 + pembrolizumab + carboplatin + nab-paclitaxel is an **investigational combination regimen** studied for the treatment of advanced or metastatic solid tumors, particularly those with SMARCA4 (BRG1) alterations. - **LY4050784** is a selective SMARCA2/BRM inhibitor, targeting synthetic lethality in tumors deficient in SMARCA4/BRG1, a chromatin remodeling gene. - **Pembrolizumab** is an anti-PD-1 monoclonal antibody immunotherapy that boosts immune response against cancer cells. - **Carboplatin** is a platinum-based chemotherapy agent that causes DNA crosslinking and apoptosis in cancer cells. - **Nab-paclitaxel** (nanoparticle albumin-bound paclitaxel) is a microtubule inhibitor causing cell cycle arrest and apoptosis, formulated to improve pharmacokinetics over conventional paclitaxel. This combination is being evaluated in a multi-arm, dose-escalation and dose-expansion phase 1 clinical trial for safety, tolerability, and evidence of antitumor activity in patients with SMARCA4/BRG1-altered tumors, including non-small cell lung cancer and other advanced solid malignancies[1][3][5].